Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox checked   Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person:  Notes to row 9: Include (i) 394,774 Ordinary Shares directly held by Yu-Hsin Lin; (ii) 407,229 Ordinary Shares underlying share options granted to Yu-Hsin Lin that are vested or will be vested within 60 days of December 31, 2024; and (iii) 1,485,067 Ordinary Shares indirectly held by Yu-Hsin Lin through Lin Bioscience International Ltd., which is our principal shareholder and the wholly-owned subsidiary of our controlling shareholder Lin BioScience, Inc.(stock code: 6696.TW). Notes to row 11: The percentage is calculated based upon an aggregate of (i) 31,826,549 Ordinary Shares outstanding as of December 31, 2024 as provided by the Issuer; and (ii) 407,229 Ordinary Shares underlying share options granted to Yu-Hsin Lin that are vested or will be vested within 60 days of December 31, 2024.


SCHEDULE 13G



 
Yu-Hsin Lin
 
Signature:/s/ Yu-Hsin Lin
Name/Title:Yu-Hsin Lin,Chief Executive Officer and Chairman
Date:01/21/2025